Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Lexicon Pharmaceuticals

Lexicon Pharmaceuticals (NASDAQ: LXRX) insider transactions

In the twelve months to 10 November 2026, executives and directors of Lexicon Pharmaceuticals reported 0 open-market sales and 9 open-market purchases of 2,089,023 shares ($2.8m), by 3 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Lexicon Pharmaceuticals shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
6 November 2026Exton MichaelChief Executive OfficerOpen-market purchase+30,064$1.66328,496Form 4
3 June 2026Debbane RaymondDirectorOption exercise+89,312—1,995,498Form 4
3 June 2026Amouyal PhilippeDirectorOption exercise+89,312—374,486Form 4
3 June 2026Barker Sam LDirectorOption exercise+89,312—213,771Form 4
3 June 2026Cheung IvanDirectorOption exercise+89,312—89,312Form 4
3 June 2026Sobecki Christopher JDirectorOption exercise+89,312—293,177Form 4
3 June 2026Sullivan Diane E.DirectorOption exercise+89,312—126,122Form 4
3 June 2026Swain Judith LDirectorOption exercise+89,312—174,486Form 4
30 April 2026Artal Participations S.a r.l.DirectorOption exercise+20,421,735—175,156,062Form 4
28 February 2026Exton MichaelChief Executive OfficerOption exercise+503,263—503,263Form 4
28 February 2026Exton MichaelChief Executive OfficerShares withheld for tax−204,831$1.47298,432Form 4
28 February 2026Coiante Scott MSVP, Chief Financial OfficerOption exercise+160,237—160,237Form 4
28 February 2026Coiante Scott MSVP, Chief Financial OfficerShares withheld for tax−54,881$1.47105,356Form 4
28 February 2026Crum Brian TSVP, General Counsel & Secr.Option exercise+33,457—363,658Form 4
28 February 2026Crum Brian TSVP, General Counsel & Secr.Option exercise+69,386—330,201Form 4
28 February 2026Crum Brian TSVP, General Counsel & Secr.Option exercise+170,163—533,821Form 4
28 February 2026Crum Brian TSVP, General Counsel & Secr.Shares withheld for tax−105,019$1.47428,802Form 4
28 February 2026DeFrancesco LisaSVP, IR and Corp CommOption exercise+24,674—40,251Form 4
28 February 2026DeFrancesco LisaSVP, IR and Corp CommOption exercise+128,190—168,441Form 4
28 February 2026DeFrancesco LisaSVP, IR and Corp CommShares withheld for tax−74,572$1.4793,869Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Lexicon Pharmaceuticals page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.